At Vyriad, we are developing the next generation of targeted cancer therapies. Oncolytic virotherapies use engineered viruses ... to selectively attack cancer cells, igniting robust immune responses and preventing cancer recurrence. We believe our viral-based therapies have tremendous potential to improve the lives of patients, inspire hope, and change the way cancer is treated. Our Phase 1-2 Clinical Studies include: Non-small cell lung cancer Squamous cell carcinoma of the head and neck Metastatic colorectal cancer Bladder cancer Other cancer types We are testing our oncolytic viruses as monotherapies or in combination with immuno-oncology drugs. Vyriad has clinical research collaboration agreements with Regeneron, Mayo Clinic, Merck KGaA/Pfizer, and other leading research and medical institutions. read more